Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)

Key facts

Sponsor

Laura Schanberg

Principal Investigator

Laura E. Schanberg, MD, MD

Duke Medical Center

Intervention

Atorvastatin(drug)

Enrollment

221 target

Eligibility

10-21 years · All sexes

Timeline

2003 – 2009

Study locations (1)

• Duke Medical Center / Duke Clinical Research Institute, Durham, North Carolina, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Pediatric systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07425730
  Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus
  Shanghai Jiao Tong University School of Medicine
• RECRUITINGNCT07128966
  Direct to Patient Minimal Risk Biospecimen and Data Collection Research
  Joined Bio
• RECRUITINGPHASE2NCT05538208
  The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
  Children's Hospital Medical Center, Cincinnati
• RECRUITINGPHASE3NCT05835310
  An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
  AstraZeneca
• RECRUITINGNANCT06586710
  Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE
  Meyer Children's Hospital IRCCS
• RECRUITINGPHASE2NCT05039619
  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
  Hoffmann-La Roche
• ACTIVE NOT RECRUITINGPHASE2NCT04179032
  Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
  GlaxoSmithKline

See all trials for Pediatric systemic lupus erythematosus →